ReviewRheumatic diseases clinics of North America2016
Patient-Reported Outcomes in Systemic Lupus Erythematosus.
Review in Rheumatic diseases clinics of North America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- Health-Related Quality of Life Improvements in Systemic Lupus Erythematosus Derived from a Digital Therapeutic Plus Tele-Health Coaching Intervention: Randomized Controlled Pilot Trial.Journal of medical Internet research · 2020Trial
- Integrating Patient-Reported Quality Measures in Systemic Lupus Erythematosus: Development of the American College of Rheumatology Implementation Guide.Arthritis care & research · 2026Article
- Facilitators and barriers to medication adherence in systemic lupus erythematosus: a qualitative study in China.Scientific reports · 2026Article
- The Relationship Between Lipid Profile as a Cardiovascular Risk Factor and Patient-Reported Physical Activity Scores: An Exploratory Analysis from the Saudi Systemic Lupus Erythematosus Cohort.Journal of clinical medicine · 2026Article
- Living with systemic lupus erythematosus in 2024: Latin American experience based on a patient survey.Clinical rheumatology · 2026Article
- Patient reported outcomes in the FDA approved drugs for systemic rheumatic diseases (2013-2024).Health and quality of life outcomes · 2025Review
- Article
- Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study.Journal of patient-reported outcomes · 2023Article
- Adaptation and validation of the Bulgarian version of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL).Clinical rheumatology · 2023Article
- Measuring What Matters: A Qualitative Study of the Relevance and Clinical Utility of PROMIS Surveys in Systemic Lupus Erythematosus.The Journal of rheumatology · 2023Article
- Article
- Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN).Lupus science & medicine · 2022Article
- Capturing the patient experience in systemic lupus erythematosus: Are widely used measures fit-for-purpose and adherent to FDA PRO guidance recommendations?Journal of patient-reported outcomes · 2022Article
- EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus.Frontiers in medicine · 2022Article
- State of the art and future directions in assessing the quality of life in rare and complex connective tissue and musculoskeletal diseases.Frontiers in medicine · 2022Review
- Patient-Reported Outcomes for Quality of Life in SLE: Essential in Clinical Trials and Ready for Routine Care.Journal of clinical medicine · 2021Review
- Symptom assessment in hypereosinophilic syndrome: Toward development of a patient-reported outcomes tool.The journal of allergy and clinical immunology. In practice · 2020Article
- Observational
- Lupus education for physicians and patients in a resource-limited setting.Clinical rheumatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Successful management of complex conditions such as systemic lupus erythematosus (SLE) and comorbid conditions benefit from patient-reported outcomes (PRO). Measuring health-related quality of life with PROs provides SLE patients with an opportunity to participate in their treatment and to facilitate better communication with the multidisciplinary team involved in their care. Health outcomes research has produced well-validated instruments that can be used across diseases; others have been specifically developed for SLE. The use of generic and SLE-specific PROs depends on needs, including population monitoring, treatment decision making, clinical trials research, and for evaluating and comparing the effect of therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.